Login to Your Account



Clinic Roundup


Wednesday, August 22, 2012
• Ocular Therapeutix Inc., of Bedford, Mass., said its travoprost punctum plug will be tested in a pilot Phase II trial to examine a two-month sustained-release drug (OTX-TP2) for ocular hypertension and glaucoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription